ASX Share rice
Tue 11 Aug 2020 - 11:28:am (Sydney)

MSB Share Price

MESOBLAST LIMITEDMSBPharmaceuticals, Biotechnology & Life Sciences

MSB Company Information

Name:

Mesoblast Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

55 Collins Street Melbourne VIC Australia 3000

Phone:

61 3 9639 6036

Full Time Employees:

83

Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director:

Dr. Silviu Itescu

Chief Financial Officer:

Mr. Josh Muntner M.B.A.

Gen. Counsel & Corp. Exec.:

Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons)

Head of Research & New Product Devel.:

Dr. Paul J. Simmons BSc, Ph.D.

Head of Pharma Partnering:

Mr. Michael Schuster M.B.A., MS, BSc, MBA

Company Overview:

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

MSB Share Price Information

Shares Issued:

583.95M

Market Capitalisation:

$2.25B

Revenue (TTM):

$33.42M

Revenue Per Share (TTM):

$0.07

Earnings per Share:

$-0.182

Profit Margin:

-1.9764

Operating Margin (TTM):

$-1.81

Return On Assets (TTM):

$-0.06

Return On Equity (TTM):

$-0.13

Quarterly Revenue Growth (YOY):

8.769

Gross Profit(TTM):

$1.36M

Diluted Earnings Per Share (TTM):

$-0.128

MSB CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-3,273,000

Dividends Paid:

$0

Capital Expenditures:

$2.25M

MSB Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-98,754,000

Net Income:

$-89,799,000

Gross Profit:

$1.36M

Operating Income:

$-80,921,000

Other Operating Expenses:

$878K

Interest Expense:

$11.70M

Income Tax Expense:

$-8,955,000

Total Revenue:

$16M

Total Operating Expenses:

$96.92M

Cost Of Revenue:

$15.36M

MSB Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$448.67M

Total Liabilities:

$171.06M

Total Stockholder Equity:

$481.05M

Other Current Liabilities:

$13.03M

Total Assets:

$652.12M

Common Stock:

$0.91B

Other Current Assets:

$6.76M

Retained Earnings:

$-469,991,000

Other Liabilities:

$59.45M

Good Will:

$134.45M

Other Assets:

$3.32M

Cash:

$50.43M

Total Current Liabilities:

$44.33M

Short-Term Debt:

$14.01M

Property - Plant & Equipment:

$826K

Net Tangible Assets:

$-102,074,000

Long-Term Investments:

$2.32M

Total Current Assets:

$62.52M

Long-Term Debt:

$67.28M

Net Receivables:

$1.74M

Short-Term Investments:

$589.59M

Accounts Payable:

$13.06M

Non Currrent Assets (Other):

$1.85M

Short-Term Investments:

$589.59

Non Current Liabilities Total:

$126.73M

MSB Share Price History

MSB News

28 Jul, 2020
21 Jul, 2020
NEW YORK, July 21, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the Oncologic Drugs Advisory Committee (ODAC) of the United States Food and Drug.
10 Jul, 2020
Mesoblast has developed a cellular therapy that may significantly reduce deaths among the most severely sick COVID-19 patients. CEO Dr. Fred Grossman joins Yahoo Finance's On the Move to discuss what this development could mean in the fight against the virus.
06 Jul, 2020
The Australian biopharma earned an important clearance to treat COVID-19 patients in the United States, which could be a sign of things to come.
NEW YORK, July 06, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that an expanded access protocol (EAP) has been initiated in the United States for.
01 Jun, 2020
NEW YORK, June 01, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that.
31 May, 2020
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
28 May, 2020
Hello, and welcome to the financial results for the period ended March 31, 2020, and corporate update for Mesoblast. Before we begin, let me remind you that in today's conference call the company will be making forward-looking statements that represent the company's intentions, expectations or beliefs concerning future events. In addition, any forward-looking statements represent the company's views only as of the date of this webcast and should not be relied upon as representing the company's views of any subsequent date.
27 May, 2020
NEW YORK, May 27, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial,.
26 May, 2020
NEW YORK, May 26, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host an analyst call to discuss the.
25 May, 2020
Key points:  Biology of Blood and Marrow Transplantation, the official publication of the American Society for Transplantation and Cellular Therapy, publishes three.
20 May, 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
13 May, 2020
Shares of Mesoblast (NASDAQ: MESO) rose as much as 27.2% today after the company announced the pricing of an offering of common stock. The stem cell developer will issue up to 43 million shares of common stock at AUD$3.20 apiece on the Australian Securities Exchange (ASX). The Sydney Morning Herald reported that Mesoblast had to push back "on demand from both new and existing institutional investors."
Mesoblast Limited (Nasdaq: MESO; ASX:MSB), a leader in cellular medicines for inflammatory diseases, announced today that it has successfully completed a capital raising of US$90 million¹ (A$138 million) via a private placement of 43 million shares to existing and new institutional investors at a price of A$3.20 per share. A significant portion of the net proceeds will be used to scale-up manufacturing of the Company’s lead product candidate remestemcel-L for the treatment of critically ill patients suffering with diseases caused by cytokine release syndromes associated with high mortality, particularly COVID-19 acute respiratory distress syndrome (ARDS). A randomized controlled Phase 2/3 trial in up to 300 patients evaluating whether remestemcel-L can reduce the high mortality in COVID-19 patients with moderate/severe ARDS is actively enrolling in up to 30 sites in the United States.
06 May, 2020
NEW YORK, May 06, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the first patients have.
30 Apr, 2020
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether its allogeneic mesenchymal stem cell therapy remestemcel-L provides a survival benefit in moderate/severe acute respiratory distress syndrome (ARDS) due to COVID-19 has commenced enrollment. More than 20 medical centers across the United States will participate in the trial which is expected to complete enrollment within three to four months, with interim analyses planned which could result in stopping the trial early for efficacy or futility.
27 Apr, 2020
The Australian stem-cell therapy developer presented promising data for COVID-19 patients days ago, but investors took some gains off the table today.
24 Apr, 2020
Key points:  83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome (ARDS) treated with two.
17 Apr, 2020
NEW YORK, April 17, 2020 -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB) today announced that results using its allogeneic mesenchymal stem cell product candidate remestemcel-L in.